CA3139086A1 - Anticorps bispecifiques contre chi3l1 et pd1 avec des effets cytotoxiques a mediation par des lymphocytes t ameliores sur des cellules tumorales - Google Patents

Anticorps bispecifiques contre chi3l1 et pd1 avec des effets cytotoxiques a mediation par des lymphocytes t ameliores sur des cellules tumorales Download PDF

Info

Publication number
CA3139086A1
CA3139086A1 CA3139086A CA3139086A CA3139086A1 CA 3139086 A1 CA3139086 A1 CA 3139086A1 CA 3139086 A CA3139086 A CA 3139086A CA 3139086 A CA3139086 A CA 3139086A CA 3139086 A1 CA3139086 A1 CA 3139086A1
Authority
CA
Canada
Prior art keywords
antibody
chi3l1
cancer
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139086A
Other languages
English (en)
Inventor
Jack A. Elias
Chun Geun Lee
Suchitra KAMLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University
Original Assignee
Brown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University filed Critical Brown University
Publication of CA3139086A1 publication Critical patent/CA3139086A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps bispécifiques ciblant simultanément à la fois CHI3L1 et la molécule de point de contrôle immunitaire PD-1. Ces anticorps présentent des effets cytotoxiques synergiques améliorés par rapport aux effets des anticorps CHI3L1 et PD-1 individuels, seuls ou en combinaison. L'invention concerne également des méthodes de traitement d'un cancer par administration des anticorps bispécifiques décrits ici.
CA3139086A 2019-05-06 2020-05-06 Anticorps bispecifiques contre chi3l1 et pd1 avec des effets cytotoxiques a mediation par des lymphocytes t ameliores sur des cellules tumorales Pending CA3139086A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962843931P 2019-05-06 2019-05-06
US62/843,931 2019-05-06
US201962876507P 2019-07-19 2019-07-19
US62/876,507 2019-07-19
US201962898324P 2019-09-10 2019-09-10
US62/898,324 2019-09-10
PCT/US2020/031710 WO2020227431A1 (fr) 2019-05-06 2020-05-06 Anticorps bispécifiques contre chi3l1 et pd1 avec des effets cytotoxiques à médiation par des lymphocytes t améliorés sur des cellules tumorales

Publications (1)

Publication Number Publication Date
CA3139086A1 true CA3139086A1 (fr) 2020-11-12

Family

ID=73050712

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139086A Pending CA3139086A1 (fr) 2019-05-06 2020-05-06 Anticorps bispecifiques contre chi3l1 et pd1 avec des effets cytotoxiques a mediation par des lymphocytes t ameliores sur des cellules tumorales

Country Status (8)

Country Link
US (1) US20220213193A1 (fr)
EP (1) EP3966247B1 (fr)
JP (2) JP2022531444A (fr)
CN (1) CN114008078B (fr)
AU (1) AU2020267491B2 (fr)
BR (1) BR112021022135A2 (fr)
CA (1) CA3139086A1 (fr)
WO (1) WO2020227431A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3876987A4 (fr) * 2018-11-07 2022-09-14 Brown University Méthodes et compositions se rapportant à des réactifs anticorps anti-chi3l1 pour le traitement de la fibrose
WO2024118611A2 (fr) * 2022-11-28 2024-06-06 Brown University Traitement du cancer du poumon non à petites cellules mutant du récepteur du facteur de croissance épidermique

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4444880A (en) 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
DE3856421T2 (de) 1987-04-27 2000-12-14 Unilever Nv Spezifische Bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992012428A1 (fr) 1991-01-11 1992-07-23 Quidel Corporation Methode de dosage en une seule phase a flux lateral sur support non spongieux
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6565808B2 (en) 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US20110009960A1 (en) 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CA2541006C (fr) 2003-10-03 2015-02-17 Brigham And Women's Hospital Ligands de tim-3 et methodes associees
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
EP3549551A1 (fr) 2007-03-20 2019-10-09 Serica Technologies, Inc. Prothèse de tendon et son procédé de fabrication
WO2010001617A1 (fr) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Utilisation d’un marqueur d’efficacité destiné à optimiser l’efficacité thérapeutique d’un anticorps pd-1 anti-humain sur les cancers
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US9579673B2 (en) 2014-06-09 2017-02-28 The Procter & Gamble Company Flushing dispensers for delivering a consistent consumer experience
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
EP3212670B1 (fr) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Polythérapie contre le cancer
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
EP3112381A1 (fr) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Anticorps bispécifiques destinés à être utilisés dans l'immunothérapie du cancer
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017124002A1 (fr) * 2016-01-13 2017-07-20 Compass Therapeutics Llc Constructions de liaison à l'antigène immunomodulateur multispécifique
EP3565596A4 (fr) * 2017-01-05 2020-12-16 Brown University Procédés et compositions se rapportant à des réactifs de type anticorps anti-chi3li
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
US10766968B2 (en) * 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
WO2019040685A1 (fr) * 2017-08-23 2019-02-28 Brown University Procédés et compositions se rapportant à des réactifs d'anticorps anti-chi3l1
CN110799546B (zh) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
EP3684819A4 (fr) 2017-09-21 2021-06-09 Yale University Anticorps anti-ykl40 et méthodes d'utilisation
WO2019062755A1 (fr) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps bispécifiques dirigés contre egfr et pd-1
US11725056B2 (en) * 2017-10-03 2023-08-15 Cedars-Sinai Medical Center Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis

Also Published As

Publication number Publication date
JP2025108549A (ja) 2025-07-23
EP3966247C0 (fr) 2026-01-07
BR112021022135A2 (pt) 2023-02-28
EP3966247B1 (fr) 2026-01-07
WO2020227431A1 (fr) 2020-11-12
US20220213193A1 (en) 2022-07-07
AU2020267491B2 (en) 2026-04-02
JP2022531444A (ja) 2022-07-06
AU2020267491A1 (en) 2021-12-02
EP3966247A4 (fr) 2023-01-04
EP3966247A1 (fr) 2022-03-16
CN114008078B (zh) 2025-05-30
CN114008078A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US20230406958A1 (en) Methods and compositions relating to anti-chi3l1 antibody reagents
US10881711B2 (en) Anti-CSPG4 reagents and methods of treating cancer
US11667726B2 (en) Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer
US20240076407A1 (en) Methods and compositions relating to bispecific anti-chi3l1 antibody reagents
US12559557B2 (en) Methods and compositions relating to anti-PD1 antibody reagents
JP2025108549A (ja) 腫瘍細胞に対するｔ細胞を介した細胞傷害効果が増大したｃｈｉ３ｌ１およびｐｄ１に対する二重特異性抗体
US20230046834A1 (en) Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
HK40068835B (zh) 具有增强的t细胞介导的对肿瘤细胞的细胞毒性作用的针对chi3l1和pd1的双特异性抗体
HK40068835A (zh) 具有增强的t细胞介导的对肿瘤细胞的细胞毒性作用的针对chi3l1和pd1的双特异性抗体
WO2024118611A2 (fr) Traitement du cancer du poumon non à petites cellules mutant du récepteur du facteur de croissance épidermique

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240815

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250429

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250429

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251031

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260113

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260326

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260408